The Genentech Foundation is a U.S.-based, private charitable foundation whose donations are made possible by contributions from Genentech. Genentech is committed to being a strong corporate citizen, and the Genentech Foundation is one of the most important ways in which we give back to our communities.
Carla Boragno, Board Chair and Senior Vice President and Global Head of Engineering and Facilities, Pharma Technical Operations
Susan Begelman, MD, Vice President, US Respiratory Franchise
Fred Brown, PharmD., Healthcare Market Director, OK|AR
Cynthia Burks, Senior Vice President, Chief People and Culture Officer
Mary Cromwell, Ph.D., Vice President, Pharma Technical Quality Drug Substance
Caroline DeMarco, Vice President, Customer Engagement, Northeast Region
Sarah Hymowitz, Ph.D., Vice President, Protein Sciences
Allen Napetian, Vice President, Site Services
Eric J. Olson, Vice President, US Product Development Regulatory
Ritish Patnaik, Ph.D., Business Development Project Leader, Pharma Partnering
Laura Resnansky, Vice President and Global Head of Clinical Operations - Immunology, Infectious Diseases, Ophthalmology, and Neuroscience (I2ON)
Patricia (Patty) Siguenza, Vice President, BioAnalytical Sciences
Geoff Teeter, Vice President, Corporate Relations
With more than 30 years of experience in engineering, manufacturing, procurement and site management, Carla brings unique insight and expertise to her role as Senior Vice President, Head of Global Engineering and Facilities for Roche. In this role, Carla is responsible for the design, construction, maintenance and life-cycle asset management for Roche’s global manufacturing network.
She is a respected mentor at Roche, in the industry and the local community. Carla serves on the Board of Directors for Bay Area Council, is the Board Chair for the Genentech Foundation, and is a member of the International Women’s Forum. Carla is a thought leader and sought-after inspirational speaker.
In 2016, Carla was recognized by the San Francisco Business Times as one of the most influential women in business in the Bay Area, and in 2017 was named to their “Forever Influential” Honor Roll. Carla was also selected in 2017 as a Hall of Fame honoree for the Northern California Real Estate Women of Influence Awards. Carla holds a Bachelor of Science, Chemical Engineering from University of California, Berkeley.
Outside of work, she can be found working in her kitchen and garden, and keeping up with the latest music trends with her teenage daughter.
“I believe that increasing access to careers in science and medicine can have an exponential impact on students, their families, and the communities they live in. I'm honored to serve as the chair of Genentech Foundation Board and excited about the opportunity to lead the Foundation through the next phase of our journey.”
Susan Begelman is the Vice President of the US Respiratory Franchise at Genentech. In this role, she leads a cross-functional team accountable for the development and implementation of integrated business and medical strategies focused on making medical progress for patients, addressing customer needs, and delivering on business objectives for this therapeutic area.
Susan is widely regarded as a respected leader with an unwavering commitment to patients. She has over fourteen years of experience in biopharmaceutical industry. Since joining Genentech in 2008, Susan has overseen product development activities and provided oversight of medical launch strategies and phase 3b/4 trials in multiple therapeutic areas that include cardiovascular disease, neuroscience, rare disease, and stroke. In her previous position, she was the Vice President of the Neuroscience, Rare Blood Disorders, Influenza, and Established Product Unit in US Medical Affairs. Prior to joining the biopharmaceutical industry, she was an academic vascular medicine physician in the Department of Cardiovascular Medicine and Medical Director of the Noninvasive Vascular Laboratory at the Cleveland Clinic for six years.
Susan received a Bachelor of Arts in Biology from the University of Pennsylvania and her Medical Doctorate from Hahnemann University School of Medicine (now called Drexel University College of Medicine) in Philadelphia. She completed her residency in internal medicine and fellowship in vascular medicine at the Cleveland Clinic. Susan is a fellow of the Society for Vascular Medicine for which she was a Committee Chair and held elected positions as a Board of Trustees Member, Secretary, and Treasurer. Susan is also a fellow of the American College of Cardiology.
"I am proud to be on the Board of the Genentech Foundation, an organization focused on investing in our local communities to remove barriers that will enable all people with a passion for science and medicine to pursue related careers."
Fred is a Healthcare Market Director in Oklahoma|West Arkansas responsible for contributing to the strategic vision and execution of business priorities across the ecosystem through his engagement with specified healthcare stakeholders across both states. He leads a diverse team of oncology, immunology, ophthalmology and neuroscience Area Managers, in addition to patient educators and access and reimbursement specialists. Collectively, they are responsible for engaging in the delivery of healthcare solutions, inclusive of patient outcomes and customer satisfaction.
Fred joined Genentech in 2014 as a Clinical Specialist, in Dallas, TX and brings a diverse background of varied experiences in sales leadership, marketing, managed care, account management and clinical practice. Prior to joining Genentech, Fred worked as a Clinical Account Manager with CVS Caremark, where he oversaw the building of clinical programming and pharmacy benefits for Large Employer Groups located in the Western United States.
He is a graduate of the Florida A&M College of Pharmacy and Pharmaceutical Sciences, where he received his Doctorate of Pharmacy degree prior to completing a PGYI Post Doctorate Residency program with CVS Caremark.
Fred is an Assistant Pastor at his church, Vice Chair of the Power to Give Foundation, and Student Mentor. He enjoys golfing, grilling and most importantly spending time with family.
Cynthia is the Chief People and Culture Officer for Genentech. In this role, she is responsible for leading people-related strategies for Genentech, which include focusing on attracting, developing, and retaining the best people to advance our mission. Cynthia and her leadership team collaborate with other Roche People and Culture teams on key projects and the implementation of global programs, processes, and systems.
Since joining Genentech in 2010, Cynthia has held several HR roles. She started her Genentech career as a senior HR business partner supporting the Pharma Technical organization and over several years took on increasingly senior roles in that global group. Prior to assuming her current position, Cynthia was vice president, Genentech Research and Early Development (gRED) HR, and a member of the Roche Group HR Leadership Team.
Prior to coming to Genentech, Cynthia worked in other industries as both a consultant and HR Leader, including as vice president of HR for The San Francisco Chronicle. In addition to a Bachelor of Science in Business, Cynthia holds an MBA in International Business from Thunderbird Graduate School and a J.D. from the University of San Francisco School of Law. She is also a licensed attorney in the State of California.
Cynthia is passionate about cultural exploration and enjoys traveling, gardening, spending time outdoors, and Latin dance in her free time.
"I am honored to have an opportunity to contribute to Genentech's long history of philanthropy through my role on the Genentech Foundation Board. I look forward to being of service to the broader community and enabling others to realize their full potential."
Based in South San Francisco, Mary began her career at Genentech in 1989 in the Pharmaceutical Development group where she developed formulations for a number of molecules in various stages of development, including Avastin®. She has held leadership positions in Protein Analytical Chemistry, Pharmaceutical Development, and Global Biologics MSAT & Global Packaging Development and has provided leadership in key initiatives including Quality by Design for Control Strategy and CMContinuum. As of June 2018, Mary became the Head of Global Quality Drug Substance. Mary received a B.S. in Chemistry from West Virginia University, an M.S.in Biophysical Chemistry from the University of California-Berkeley, and a Ph.D. in Pharmaceutical Sciences from the University of Colorado-Denver.
"I am excited to be a Genentech Foundation Board member because of the focus the Foundation has to support students from underrepresented groups to obtain their degrees in STEM. This includes ensuring food security, facilitating the transition from community colleges to four year universities, and funding programs that provide additional resources to these students."
As a member of the Customer Engagement Leadership Team on the Customer, Marketing and Government (CMG) Team at Genentech, Caroline partners with the National Accounts, Medical Affairs and Therapeutic Area Squad Teams to ensure that their innovation reaches the patients they serve and they are responsible for developing the skills & capabilities of the Northeast regional team.
Caroline has over three decades of pharmaceutical experience. With a finance background, her experience spans sales, contracting, finance, marketing, human resources, payer, strategic planning, commercial operations, capability building and talent management including global responsibilities. Before joining Genentech in 2020, Caroline was at GlaxoSmithKline (GSK) as VP, Global & Implementation Lead where she was responsible for driving the strategic change & implementation plan for the transformation and subsequent launch a new Biopharma company and the separation and launch of a new global Consumer Healthcare Company for GSK.
Outside of work, Caroline sits on the Board of the Trustees for The Haverford School (Haverford.org) in Haverford, PA--a private all boys school that has been educating boys to be men of character since 1884. Caroline is based in Philadelphia, PA and is a leader serving her community in several capacities. She is a member of the Executive Forum of Women (foew.com), the Immediate President of The Penn Towne Chapter of The Links, Inc. 2015-2019 (penntownelinks.org), a Charter member the Omega Mu Omega Chapter of Alpha Kappa Alpha Sorority, Inc. (AKA1908.org) and a member of Jack & Jill of America, The Philadelphia Chapter (jackandjillinc.org).
Sarah Hymowitz is the Vice President of Protein Sciences with Genentech Research and Early Development. In this role she leads groups responsible for Large Molecule drug discovery and protein-related support of Large Molecule, Small molecule and discovery projects including the departments of Antibody Engineering, Structural Biology, Protein Chemistry, Biomolecular Resources, Microchemistry, Proteomics and Lipidomics as well as the Department of Research Informatics & Software Engineering. Collectively, these groups create biological reagents, data and informatics tools that further our understanding of the structure, function, and regulation of proteins of therapeutic interest and contribute to the discovery of large and small molecule therapeutics.
Sarah is a member of the Research Leadership Team and contributes to research portfolio decisions as a member of the Research Review Committee. She chairs the Proteins Leadership Team, which is responsible for large molecule drug discovery in collaboration with discovery biology groups.
Sarah earned a B.A in Chemistry from Swarthmore College followed by a Ph.D. in Biophysics from the University of California, San Francisco. She joined Genentech as a postdoctoral researcher in 1999 and was subsequently hired as a Scientist in 2002. Throughout her career, Sarah has played leadership roles in basic research, antibody and small molecule drug discovery projects, and has contributed to over 85 scientific publications and patent applications. She is passionate about mentoring and developing talent.
"I am grateful to be a member of the Board of the Genentech Foundation and am inspired by the creativity and impact of our grantees and partner organizations."
Allen is Vice President and Head of Site Services at Genentech. He is accountable for Genentech's corporate real estate portfolio, site engineering, facilities management, utilities operations, security, environmental health and safety, environmental sustainability, workplace strategies, transportation, and several key workplace services.
Allen has over twenty-eight years of site and global experience in the pharmaceutical industry across clinical and commercial Manufacturing and Quality. He is an execution-oriented and multi-cultural leader with a proven track record of partnership and collaboration in drug substance, drug product, and supply chain management operations. With a unique combination of creativity, empathy and results focus, Allen builds strong teams and unlocks high performance and engagement through his servant leadership style. He has successfully delivered on ambitious and innovative change initiatives. He is also recognized for leading organizational transformations with a genuine interest in employee development, diversity and well-being. Allen first joined Genentech in 1992 and has since worked in South San Francisco, Singapore, and Hillsboro locations.
Allen graduated from the University of California at Davis with a Bachelor of Science degree in Biology and earned an MBA from Saint Mary’s College of California. Outside of work, he can be found listening to vinyl records with his son at the local music store, spending time with his wife walking through downtown Millbrae, and riding his motorcycle through the Bay Area.
"It's a privilege to be a part of the Genentech Foundation as there is no greater honor than to be of service to our community and to foster a better future for others."
Eric J. Olson is currently the Vice President of US Product Development Regulatory. In this role, Eric manages the policy, intelligence and commercial regulatory affairs (CORA) groups in PDR. He sits on the PDR Leadership Team contributing to the overall direction of the global Regulatory group within the company.
While previously based in Basel, Switzerland he served as business lead for Product Development’s (PD) Smarter Information Management initiative, a multi-year innovation project aimed toward transforming the way PD uses its vast clinical information. Additionally, Eric was the Head of CORA, Director of PD Projects for Genentech’s former President Sue Hellmann and one of the company’s lobbyists in Washington, DC. Eric also serves as the Site Head for Product Development in South San Francisco and on the Board of the Genentech Foundation, a private charitable foundation the company created to give back to its local community.
Prior to joining Genentech, Eric was Chief of Staff to U.S. Representative Anna G. Eshoo - managing all legislative, constituent and administrative functions in her Washington, D.C. office. He has held legislative roles for former U.S. Senate Democratic Leader Thomas Daschle, Rep. Eshoo, and former Rep. Norm Mineta.
Eric graduated from Santa Clara University in 1995 with a B.A. in Political Science and minor in Communication. He lives in Redwood City, CA with his wife and two daughters. Hobbies include playing and coaching sports, reading and learning about wine. He played football at Santa Clara University but after many years and many knee surgeries, he currently prefers non-contact sports such as distance running and triathlon.
"I'm honored to serve on the Genentech Foundation Board and build upon the company's legacy of providing support to the next generation of pioneering scientists from our local community."
Ritish joined Genentech in 2020 as a Business Development Project Leader in the Pharma Partnering group. He works closely with scientists, lawyers, and financial analysts to identify and partner external therapeutic, diagnostic and analytical technologies with Genentech. Ritish focuses on translational genomics and computational drug discovery methods for Genentech Research and Early Development, as well as multi-omic and real-world patient data to enable Roche’s clinical trials. He also co-leads Pharma Partnering efforts to engage with the venture capital community.
Ritish earned a B.S. in biomedical engineering from Columbia University, a M.S. in management science and engineering from Stanford University and a Ph.D. in bioengineering from Stanford. While at Stanford, he gained expertise in data mining, machine learning and assay development by inventing a computational method to discover molecules that represent cancer in blood and creating a low-cost sequencing test for these molecules. Ritish also co-founded and grew a social venture to modernize cervical cancer screening in low-income areas (Luso Labs), while mentoring high school, college, and graduate students through research experiences and biodesign programs.
Laura joined Genentech in 1999 working in clinical operations on Pulmozyme and supporting the thromoblytics franchise. Her background is in Nursing and she began her career in drug development as a Study Coordinator for NIH sponsored studies. Following this she worked at a CRO as a Monitor and then moved on to a role in Drug Safety at Boehringer Ingelheim. Throughout her 25 years in the industry her work experience has spanned multiple roles and across various therapeutic areas including respiratory, cardiovascular diseases, immunologic disorders, rheumatology, ophthalmology, and neurological diseases.
Patty leads a top-notch department dedicated to enabling drug development by creating bioanalytical strategies, methods, and providing foundational data for non-clinical and clinical studies to advance Genentech molecules through all stages of drug development and post marketing.
Patty joined Genentech in the late 1980’s, after receiving her B.S. in Clinical Sciences, San Francisco State University, having attended College of San Mateo prior to SFSU. Throughout her career, she has made significant contributions to Genentech’s US and ex-US product development and approvals in the areas of oncology, autoimmunity, and asthma drugs. Patty strongly believes in Genentech’s commitment to patients, and the endless possibilities to advance science.
In 2020, The San Francisco Business Times recognized Patty as one of the “Most Influential Women in the Bay Area”. Patty is very passionate about education and people development, volunteering her time mentoring professionals and college students, as well as recent graduates. She chairs the San Mateo County Community Colleges Foundation Board, is a member of the SFSU Foundation Board, and serves the Cañada College President’s Advisory Group.
Geoffrey P. Teeter is Vice President, Corporate Relations at Genentech. In this role, Geoff leads the company’s communication strategy and oversees the activities of the Corporate Relations department including corporate and product public relations, corporate branding, science communications, internal communications, corporate and employee giving and digital strategy and channels.
Geoff is a member of the global Communication Leadership Team and serves as the North American Communications Lead for the Roche Group in the United States. He is a member of the Board of Directors of both the Genentech Foundation and the Genentech Patient Foundation.
During his tenure with the company, Geoff has developed and implemented a number of communications initiatives and strategies that have helped strengthen Genentech's corporate reputation and supported the company's goal of being a great place to work. Prior to joining Genentech, Geoff held roles at Burson-Marsteller and at CIBA-Geigy Pharmaceuticals Division. He holds a bachelor's degree in mass communication from St. Bonaventure University.
"It is an honor to be a member of the Genentech Foundation Board of Directors. During my career at Genentech some of my most inspiring moments have been related to the work we are doing in science education and supporting our local communities. I’m really excited about our progress to date and our plans for the future."